New collaboration aims to enhance biologics through advanced cell line technology.
- Collaboration focuses on high-performance cell line development
- Aims to support next-generation biologics
- Partnership enhances biopharmaceutical production
OneCyte and Kemp Proteins have announced a new strategic partnership aimed at advancing cell line development for next-generation biologics. This collaboration is designed to optimize the production of high-performance cell lines, which are crucial for biopharmaceuticals. By combining their expertise, the companies hope to increase the efficiency and quality of biologics manufacturing.
The partnership will leverage OneCyte's innovative cell line technologies alongside Kemp Proteins' proficiency in protein engineering. Together, they aim to enhance the capabilities of cell lines, addressing the growing demand for effective biologic products. This initiative is expected to streamline development processes and improve outcomes in the biopharmaceutical sector.
The collaboration marks a significant step forward in the field of biologics while addressing the increasing need for advanced therapeutic solutions. Both companies are committed to pushing the boundaries of what is possible in cell line development, ensuring they meet the evolving demands of the health market.
